Contact
searchSearch
HMP Global
Login

Myeloproliferative Neoplasms Excellence Forum Excellence Forum

MPN Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Claire Harrison, MD
Videos
MAJIC-PV Study Indicates Ruxolitinib Treatment Yields Superior Responses for Patients With Polycythemia Vera
06/21/2023
Claire Harrison, MD, presents results from the phase 2 MAGIC-PV trial, which indicate that ruxolitinib treatment yielded superior event-free survival and complete responses vs best available therapy for patients with...
Claire Harrison, MD, presents results from the phase 2 MAGIC-PV trial, which indicate that ruxolitinib treatment yielded superior event-free survival and complete responses vs best available therapy for patients with...
Claire Harrison, MD, presents...
06/21/2023
Oncology
Claire Harrison, MD
Videos
Second-Line Therapy for Patients With Polycythemia Vera: A Review of Data on Ruxolitinib
05/04/2023
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
How to Determine When First-Line Therapy for Polycythemia Vera is Failing
05/04/2023
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
Aims of Treatment and Choice of First-Line Therapy for Patients With Polycythemia Vera
05/04/2023
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
Diagnostics and Risk Stratification for Patients With Polycythemia Vera
04/19/2023
Claire Harrison, MD, discusses the latest updates in diagnostics and risk stratification of polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
Claire Harrison, MD, discusses the latest updates in diagnostics and risk stratification of polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
Claire Harrison, MD, discusses...
04/19/2023
Oncology
Dr Mesa
Videos
Ruben Mesa, MD, Discusses Momelotinib in Patients With Myelofibrosis
03/16/2022
Ruben Mesa, MD, discusses the phase 3 MOMENTUM trial evaluating momelotinib in patients with MF who are symptomatic and anemic.
Ruben Mesa, MD, discusses the phase 3 MOMENTUM trial evaluating momelotinib in patients with MF who are symptomatic and anemic.
Ruben Mesa, MD, discusses the...
03/16/2022
Oncology
Interview
Inflammation Makes for a Logical Therapeutic Target in MPNs
03/15/2018
Angela Fleischman, MD, discusses the role of inflammation in MPN transition to leukemia.
Angela Fleischman, MD, discusses the role of inflammation in MPN transition to leukemia.
Angela Fleischman, MD, discusses...
03/15/2018
Oncology
Videos
Key Insights: MPN and MDS
02/27/2018
Recent advances in understanding the biology of MPN have spurred significant discoveries that have the potential to change the paradigm of how MPN and MDS are diagnosed and treated.
Recent advances in understanding the biology of MPN have spurred significant discoveries that have the potential to change the paradigm of how MPN and MDS are diagnosed and treated.
Recent advances in understanding...
02/27/2018
Oncology
Videos
Best of the Day: from the 2016 Annual Hematology Meeting - CML & MPN
02/27/2018
Drs Joseph R Mikhael and Ruben A Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with chronic myelogenous leukemia and myeloproliferative neoplasms.
Drs Joseph R Mikhael and Ruben A Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with chronic myelogenous leukemia and myeloproliferative neoplasms.
Drs Joseph R Mikhael and Ruben A...
02/27/2018
Oncology
Interview
JAK2 Assay Approval Supports Adherence to MPN Diagnostic Guidelines
01/30/2018
Christoph Menzel, PhD, discusses the importance of JAK2 testing to support treatment decision-making for MPN.
Christoph Menzel, PhD, discusses the importance of JAK2 testing to support treatment decision-making for MPN.
Christoph Menzel, PhD, discusses...
01/30/2018
Oncology

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use